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40
41 Abstract 
42 Background: Insomnia is highly prevalent in individuals recovering from Alcohol Dependence 
43 (AD) and increases their risk of relapse. Two studies evaluating Cognitive Behavioral Therapy for 
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44 Insomnia (CBT-I) have demonstrated its efficacy in non-Veterans recovering from AD. The aim 
45 of this study was to extend these findings in an 8-week trial of CBT-I in Veterans.
46 Methods: Veterans recovering from AD were randomly assigned to 8 weeks of treatment with 
47 CBT-I (N=11) or a Monitor-Only (MO [n=11]) condition and were evaluated 3 (N=21/22) and 6 
48 months post-treatment (N=18/22). The primary outcome measure was the Insomnia Severity 
49 Index (ISI) score. Secondary outcome measures were sleep diary measures, percent days 
50 abstinent (PDA), and scores on the Dysfunctional Beliefs and Attitudes About Sleep scale 
51 (DBAS), Sleep Hygiene Index (SHI), Penn Alcohol Craving Scale (PACS), Quick Inventory of 
52 Depressive Symptoms (QIDS), State-Trait Anxiety Inventory-Trait (STAI-T) scale and SF-12. 
53 Mixed effects regression models, adjusted for race, evaluated differences in outcomes between 
54 the groups over a 6-month period (clinicaltrials.gov identifier=NCT01603381).
55 Results: Subjects were male, aged 54.5 (SD=6.9) years, and had 26.4 (SD=26.3) days of 
56 abstinence before their baseline evaluation. CBT-I produced a significantly greater 
57 improvement in model-based estimates than MO (mean change at 6 months compared to their 
58 baseline) for ISI, sleep latency from a daily sleep diary, DBAS mean score, and SHI total score.  
59 PDA and QIDS improved over time, but there was no difference between the groups. PACS, 
60 STAI-T or SF-12 scale did not show any improvement from their baseline scores. 
61 Conclusions: CBT-I treatment demonstrated substantial efficacy in reducing insomnia, 
62 associated negative cognitions and improving sleep hygiene in Veterans during early recovery, 
63 though it did not reduce drinking behavior. 
64 Introduction 
65 Insomnia occurs in about two-thirds of recovering patients with alcohol dependence (AD), an 
66 estimated prevalence that is up to 6.5 times that of the general population (Chakravorty et al., 
67 2016). Comorbid insomnia is linked with an increased risk of relapse during recovery from AD, 
68 as well as suicidal behavior, daytime dysfunction, and decreased well-being (Chakravorty et al., 
69 2016). 
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70 Prior studies have investigated pharmacologic and behavioral treatments for insomnia in AD. 
71 Treatment with medications such as gabapentin, trazodone, and quetiapine has not 
72 consistently been shown to be beneficial in patients with these co-occurring disorders 
73 (Chakravorty et al., 2016). In contrast, in this population, the efficacy of behavioral treatments 
74 such as progressive muscle relaxation and cognitive behavior therapy for insomnia (CBT-I) is 
75 well demonstrated. CBT-I, a multicomponent treatment, consists of both behavioral (e.g., sleep 
76 restriction, stimulus control) and cognitive (e.g., cognitive restructuring) strategies, which target 
77 factors that perpetuate insomnia over time. Two randomized trials evaluated the efficacy of 
78 CBT-I in patients with AD. Currie and colleagues (2004) compared CBT-I to two other 
79 conditions—a self-help condition (reading a manual along with telephone support sessions) and 
80 a waitlist control (Currie et al., 2004)—in 60 community-dwelling individuals with AD. Subjects 
81 treated with CBT-I and the self-help condition demonstrated significant improvements in sleep 
82 continuity relative to pre-treatment and greater improvements than a waitlist control, 
83 improvements that were maintained for 6 months after treatment. They found no effect of 
84 CBT-I on alcohol use. Arnedt and colleagues (2011) conducted a randomized controlled trial 
85 (RCT) of an 8-session version of CBT-I (N=9) or a behavioral placebo control (N=8) (Arnedt et al., 
86 2011). CBT-I-treated subjects showed significantly greater improvements in self-reported Sleep 
87 Efficiency (SE) and Wake After Sleep Onset (WASO) than the control group, but no difference in 
88 alcohol consumption. Thus, although both studies showed that CBT-I improved insomnia, 
89 neither found that it reduced alcohol consumption. 
90 While CBT-I may be efficacious for insomnia among community-dwelling patients with AD, it 
91 has not been evaluated in Veterans with AD, a population with high prevalence rates of both 
92 insomnia and AD (Tsai et al., 2014, Kelsall et al., 2015, Seal et al., 2011, Alexander et al., 2016, 
93 Martin et al., 2017). Further, if CBT-I improves insomnia, does it also improve alcohol 
94 abstinence, as insomnia is a risk factor for relapse (Chakravorty et al., 2016)? The primary aim 
95 of this pilot study was to evaluate the efficacy of an 8-week CBT-I treatment for improving 
96 insomnia and at 3- and 6-month post-treatment follow-up in Veterans with AD during early 
97 recovery. Secondary aims of the study were to compare CBT-I to a Monitor-Only (MO) control 
98 group on alcohol-related outcomes and to assess the effect of CBT-I treatment on daytime 
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99 functioning measures such as depressive symptoms, anxiety symptoms, and self-reported well-
100 being. 
101
102 Materials and Methods
103 We conducted an 8-week, randomized, parallel-group trial of CBT-I in 22 individuals.  The study 
104 was conducted at the Cpl. Michael J Crescenz VA Medical Center (CMCVAMC) in Philadelphia, 
105 PA.  The CMCVAMC Institutional Review Board approved the study and all subjects gave 
106 informed consent prior to participating in the study.  Upon successful completion of screening, 
107 prospective subjects were randomly assigned using the Research Randomizer software 
108 (Urbaniak and Plous, 2013) to receive the active treatment or to a Monitor-Only arm (MO) and 
109 followed up in-person for 8 consecutive weeks. They returned for follow-up visits 3 and 6 
110 months later.
111 Subjects. Subjects were recruited using flyers posted within the medical center or as direct 
112 referrals from their care providers in addiction psychiatry, general psychiatry, and primary care 
113 clinics. Subjects were included if they were: Veterans aged 18-65 years; reported insomnia 
114 symptoms, as assessed by a score of ≥ 8 on the Insomnia Severity Index; had < 1 year of 
115 abstinence from risky drinking, a past-year diagnosis of alcohol dependence as determined by 
116 the MINI (Sheehan et al., 1998), no significant evidence of alcohol withdrawal [Clinical Institute 
117 Withdrawal Assessment (CIWA) scale score ≤ 8 (Sullivan et al., 1989)], ≥ 3 consecutive days of 
118 abstinence from alcohol prior to a portable home sleep apnea test (HST); and were capable of 
119 communicating in English and giving written informed consent.
120 Subjects were excluded if they had a past-year diagnosis of a drug use disorder other than 
121 nicotine or cannabis, current unstable or serious psychiatric conditions (e.g., schizophrenia, 
122 bipolar disorder), unstable or serious medical illness, chronic pain leading to insomnia, evidence 
123 of severe cognitive impairment on the Blessed Orientation-Memory-Concentration test 
124 (Blessed et al., 1968), or untreated, moderate-to-severe obstructive sleep apnea (OSA) 
125 diagnosed by HST or non-adherence with positive airway pressure (PAP) treatment, defined as 
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126 PAP use <60% of the days with use ≤ 4 hours per night on the nights they used the device, 
127 based on their objective PAP compliance data. 
128 Procedures. Prospective subjects underwent screening over a 2-4 week period, during which 
129 time staff comprehensively assessed their sleep, medical, and psychiatric disorders, which 
130 included an HST and clinical evaluation for sleep-related disorders.  Subjects were required to 
131 be totally abstinent from alcohol for ≥ 3 consecutive days prior to the HST. Following screening, 
132 subjects entered an 8-week treatment phase with weekly visits to the research clinic. They 
133 were followed up at 3 and 6 months post-treatment to evaluate changes in sleep, drinking, and 
134 daytime outcomes. All questionnaires were completed during the clinic visit, except sleep 
135 diaries, which were filled out at home.
136 Treatments. Cognitive Behavioral Therapy for Insomnia (CBT-I): The CBT-I treatment was based 
137 on the published treatment manual CBT-I (Perlis et al., 2005) and established procedures at the 
138 Penn Behavioral Sleep Medicine clinic. Eleven subjects met individually with the study clinician 
139 (JF), a certified behavioral sleep medicine provider, for CBT-I. Session 1 served as an orientation 
140 session and the initiation of Sleep Restriction Therapy (SRT) (Spielman et al., 1987a, Spielman et 
141 al., 1987b) and Stimulus Control therapy (Bootzin and Perlis, 2011, Bootzin, 1972, Bootzin, 
142 1984). Sleep restriction therapy required that subjects limit their time in bed to an amount 
143 similar to their average total sleep time.  Subsequently, the provider gradually increased time in 
144 bed in 15-30 minute increments to the targeted sleep duration while ensuring that 85-90% of 
145 the time in bed was spent sleeping. The sleep opportunity was decreased by 15-30 minutes if 
146 the time spent sleeping did not reach 85% or decreased below 85%.  Stimulus control 
147 instructions limit the amount of time one may spend in the bedroom while awake and the kind 
148 of behaviors one may engage in while in the bed or the bedroom, in order to strengthen the 
149 relationship between the bed or bedroom and consolidated sleep, i.e., with the subject lying 
150 down to sleep only when sleepy and avoiding the bed for anything other than sleep or sexual 
151 activity. Sessions 2 covered Sleep Hygiene (Stepanski and Wyatt, 2003, Zarcone, 1989, Posner 
152 and Gehrman, 2011), which addresses behaviors that influence sleep quality and quantity, such 
153 as arising at the same time every day; avoiding alcohol, especially in the evenings; and avoiding 
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154 daytime naps. Sessions 4-7 were dedicated to a titration of time in bed and ensuring patient 
155 adherence. Session 4 also delivered a specific form of cognitive therapy, which was introduced 
156 initially in Session 3 (as a request to the patient to monitor his maladaptive cognitions for that 
157 week). The Cognitive Therapy was modeled on Barlow's approach to the cognitive restructuring 
158 of catastrophic thinking as it occurs with panic disorder (Barlow, 1992). This approach was 
159 adapted to address catastrophic thinking in relation to insomnia, such as “I will never be able to 
160 sleep on my own, ever again.” The final session (session 8) focused on insomnia relapse 
161 prevention strategies. Adherence with CBT-I was assessed by calculating the difference 
162 between the prescribed Time-in-Bed and the reported Time-in-Bed on the sleep diaries. 
163 Deviations ≥ 105 min each week were recoded into a dichotomous measure with subjects being 
164 considered compliant or noncompliant for that specified week (Perlis et al., 2004).  Standard 
165 Care Monitor-Only Condition (M.O.): The eleven subjects in this condition were seen weekly by 
166 the study coordinator to complete and review assessments of their sleep, alcohol use, and 
167 daytime functioning. The review was interrogative in nature and no directed form of therapy 
168 was provided to help with sleep or reduce alcohol use, similar to other CBT-I studies that have 
169 used this control condition (Jungquist et al., 2010). As with the CBT-I sessions, the duration of 
170 the initial MO session was 45 minutes and each of the follow-up sessions was 30 minutes. MO 
171 subjects continued to receive ongoing medical and or mental health care. This condition 
172 controlled for the effects of observation and self-monitoring (Frank and Kaul, 1978, McCarney 
173 et al., 2007).  Group therapy provided to Veterans at CMCVAMC for substance use disorders: 
174 The primary psychosocial treatment for addictive disorders at CMCVAMC is group therapy. It is 
175 grounded in the principles of 12-step meetings and Motivational Enhancement Therapy and 
176 modified by individual clinicians using either relapse prevention techniques or behavioral 
177 therapies (by employing techniques from Rational Emotive Behavioral Therapy and Cognitive 
178 Behavioral Therapy). No sleep-related intervention is employed in these groups but the 
179 importance of having a good sleep pattern is encouraged in one of the sessions to help prevent 
180 relapse.
181 Assessments. 
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182 Sleep. 
183 a) Insomnia Severity Index (ISI) (Bastien et al., 2001) is a 7-item, self-report questionnaire 
184 that yields a global score from 0-28, with higher scores representing greater insomnia 
185 severity. The ISI was the primary outcome measure in this study and was recorded every 
186 2 weeks during treatment and at the post-treatment assessment visits; 
187 b) Subjects completed the Perelman School of Medicine version of the daily sleep diary to 
188 assess subjective sleep variables at every treatment visit and at the 3- and 6-month 
189 post-treatment visits. The sleep diary variables used in this study included Sleep Latency 
190 (SL, time in minutes required to fall asleep initially); Wake After Sleep Onset time 
191 (WASO, duration of wakefulness during the night in minutes), Number of Awakenings 
192 (NAW, frequency of awakenings each night); and Total Sleep Time (TST, total time of 
193 sleep each night, in minutes). 
194 c) Dysfunctional Beliefs and Attitudes About Sleep Scale (DBAS) (Morin et al., 2007). This 
195 16-item questionnaire was completed at all assessment visits to evaluate unhelpful 
196 sleep-related cognitions. 
197 d) Sleep Hygiene Index (SHI) (Mastin et al., 2006). This 13-item, patient-reported 
198 questionnaire assessed sleep hygiene behaviors at all assessment visits.
199 e) Epworth Sleepiness Scale scores (ESS) (Johns, 1991). This 8-item self-report measure 
200 evaluated daytime sleepiness at all assessment visits. 
201 Alcohol Consumption. 
202 a) Time Line Follow-back interview (Sobel and Sobell, 1992) was used to assess the percent 
203 days abstinent (PDA) for the 90 days during the baseline screening phase, during the 8-
204 week treatment phase, and at the 3- and 6-month follow-up visits. Heavy drinking was 
205 defined as the consumption of  5 alcoholic drinks in a day.
206 b) Penn Alcohol Craving Scale (Flannery et al., 1999), a 5-item, self-report measure, was 
207 used to evaluate alcohol craving over the preceding 7 days at all assessment visits. 
208 Daytime functioning.
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209 a) Quick Inventory of Depressive Symptoms (QIDS) (Rush et al., 2003). This 16-item self-
210 report instrument assessed depressive symptoms at all assessment visits.
211 b) Trait sub-scale from the State-Trait Anxiety Inventory (STAI) (Spielberger et al., 1970). 
212 This 40-item subject-rated scale was used to evaluate anxiety symptoms at all 
213 assessment visits.
214 c) Short Form 12-item (SF-12) (Ware et al., 1996) inquired about physical and mental 
215 wellbeing with the Physical and Mental Composite Scores (PCS and MCS), at baseline, 
216 weeks 4 and 8 of the treatment phase, and at 3- and 6-month post-treatment follow-up 
217 visits. 
218 Statistical Analysis. We assessed baseline demographics and other characteristics across the 
219 treatment groups using a Wilcoxon Sign-rank test, t-test, chi-square or Fisher’s test, as 
220 appropriate. Because the treatment groups were not balanced on self-reported race it was 
221 treated as a confounding variable in the analysis of longitudinal data. We used the intent-to-
222 treat principle to analyze the data. Linear mixed effects regression models employing maximum 
223 likelihood estimation were used to compare the outcome trajectory by treatment conditions 
224 across 10 time points (8 weekly treatment visits and 2 post-treatment follow-up visits). 
225 Exceptions to this rule were made with the ISI score, which was evaluated during 7 visits 
226 (baseline, treatment visits 2, 4, 6 and 8 and the two follow-up visits), and the PCS and MCS 
227 scores of the SF-12 scale, which was completed during 5 visits (treatment weeks 1, 4, and 8 and 
228 the two follow-up visits). Each model considered categorical, continuous, and quadratic trends 
229 over time and treatment by time interactions. We evaluated each of the models for the 
230 appropriate variance-covariance matrix structure of random effects. The final models for each 
231 variable were selected for the most parsimonious Bayesian Information Criterion score. The 
232 treatment effect was measured by the time-by-group interaction, where a statistically 
233 significant interaction indicated a difference in the outcome over time by group. Results are 
234 presented as scores of the model-estimated change from baseline along with their 95% 
235 confidence intervals. Remission from insomnia was defined by a subject-specific, model-
236 estimated ISI total score <8. Treatment response was defined as a decrease of >8 points in the 
237 ISI total score (Morin et al., 2011). 
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238 A Generalized Estimating Equation was used to model the days abstinent from alcohol over 
239 time across treatment groups using a natural log link function and an independent within-group 
240 correlation structure, considering the Poisson distribution of PDA. The four time-segments used 
241 in this analysis were pretreatment (90 days), treatment (56 days), and 3- and 6-month post-
242 treatment periods (each 90 days). We used the predicted value for each outcome generated 
243 from the longitudinal analysis to compute the difference scores and generate graphs, except in 
244 the evaluation of effect sizes (for ISI). The within-group effect sizes from baseline were assessed 
245 using the mean and standard deviation of the change score from baseline. Here, values of 0.20, 
246 0.50, and 0.80 represent small, moderate, and large effect sizes, respectively (Friedmann et al., 
247 2008). We used Stata 13.0 IC (StataCorp, 2011) to conduct statistical analysis and Stata 15.0 to 
248 create the graphs as Stata 13.0 was no longer available.
249
250 Results
251 Subjects. Twenty-four of 109 prospective subjects were eligible for the study, of whom two 
252 opted not to participate before randomization; see Figure 1 for a CONSORT flow chart. We 
253 randomly assigned 22 subjects to the CBT-I (N=11) or Monitor-Only (MO [n=11]) condition. 
254 Sixteen of the 22 subjects were receiving psychosocial treatment for their AD, including 7 of 11 
255 subjects in the CBT-I arm and 9 of 11 subjects in the MO arm, (p=NS, not statistically 
256 significant). All 22 subjects completed the 8-week treatment period and 21 subjects completed 
257 the 3-month and 18 completed the 6-month post-treatment follow-up visits. During their study 
258 participation, 13 subjects relapsed to alcohol use (7 in the CBT-I arm and 6 in the MO arm, 
259 p=NS). Four subjects dropped out during the post-treatment follow-up period (2 in the CBT-I 
260 arm and 2 in the MO arm, NS). A comparison of subjects who dropped out of the study with 
261 those who completed it showed no difference on treatment allocation, pretreatment PDA, age, 
262 race, marital status, education or baseline ISI scores (p’s all NS). 
263 Baseline Demographics and Clinical Measures (Table 1). On average, subjects were middle-
264 aged, male, and African American (AA). The groups differed only on race, as the MO group was 
265 comprised entirely of AAs, while only 45% of the CBT-I arm was (p = 0.01). On average, subjects 
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266 initially reported insomnia of moderate severity at baseline, with a mean sleep latency of 51 
267 minutes.  They were abstinent on about 26% of days during the 90-day pretreatment period 
268 and reported heavy drinking on 80% of drinking days. There was no baseline treatment-group 
269 difference on the use of alcohol as a sleep aid.  
270 Sleep Outcomes. 1) Insomnia Severity Index. Both groups showed a decrease in insomnia 
271 scores. However, at the end of treatment, there was a greater reduction in the ISI total score in 
272 the CBT-I group than the MO group, a difference that persisted at the 3- and 6-month follow-up 
273 visits (see Table 2 and Figure 2). When compared to their baseline values, the within-group 
274 magnitude of improvement at the end of treatment, and at the 3-month and 6-month follow-
275 up visits, were 1.9, 2.2 and 1.9 for the CBT-I group, compared to 0.4, 0.5 and 0.4 for the MO 
276 group. All CBT-I treated subjects were remitted from their insomnia at week 8, an effect that 
277 was maintained until the 6-month post-treatment follow-up visit. In contrast, none of the 
278 subjects in the MO arm were in remission from insomnia at the end of treatment or at the post-
279 treatment follow-up visits; 2) Sleep diary variables. i) In a quadratic model, there was a 
280 treatment effect on SL, such that it initially decreased in the CBT-I group, but then increased in 
281 the post-treatment phase while remaining lower than in the MO at the 6-month follow-up visit 
282 (Figure 3). Exclusion of an outlier in the CBT-I group did not change the results; ii) WASO, TST 
283 and NAW – there was no treatment effect (Supplementary Figure 2); 3) Dysfunctional Beliefs 
284 and Attitudes About Sleep scale. There was a significant treatment effect, such that CBT-I 
285 subjects reported a lower DBAS mean score than the MO subjects (Figure 4). 4) Sleep Hygiene 
286 Index. There was a significant treatment effect, such that the CBT-I group reported a greater 
287 decrease in SHS total score over time, (Supplementary Figure 1). 5) Epworth Sleepiness Scale. 
288 Although there was not a significant effect of the intervention or time, there was a non-
289 significant Treatment x Time interaction effect (p=0.05). 6) Treatment adherence with CBT-I. 
290 Only one subject met criteria for non-adherence, which occurred at visits 3, 4, 6, and 7 and at 
291 the post-treatment follow-up visits.
292 Alcohol Consumption. 1) Percent Days Abstinent (PDA). At the beginning of treatment, 21 
293 subjects were abstinent for all days in the preceding week; 1 subject in the MO arm had one 
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294 drink on a single day. Our longitudinal assessment of PDA indicated that both groups improved 
295 over time, with no between-group difference (Supplemental Figure 3). During the 8 weeks of 
296 treatment, 18 subjects reported remaining abstinent from alcohol (10 in the CBT-I arm and 8 in 
297 the MO arm). At the 3-month follow-up visit, 14 of these 18 subjects reported remaining 
298 abstinent from alcohol (8 in the CBT-I arm and 6 in the MO arm, 2 = 0.38, p = 0.50). Of these 14 
299 subjects, 8 subjects remained abstinent at the 6-month follow-up visit (4 subjects in each 
300 treatment group). The subjects who relapsed during the study frequently drank heavily at those 
301 times and all received concomitant psychosocial treatment to reduce their drinking. Subjects 
302 who relapsed to drinking were not differentiated from the other participants on age, years of 
303 education, marital status, race, baseline PDA or ISI score, or treatment arm, or whether they 
304 received psychosocial treatment for AD. 2) Alcohol craving (PACS). There was no evidence of 
305 any change in the PACS score with time. 
306 Daytime Functioning. We found that depressive symptoms, as measured by the QIDS, 
307 improved over time equally in both groups.  There was no significant change in either State-
308 Trait Anxiety Inventory (STAI)-trait scale, PCS, or MCS (SF-12) scores.
309
310 Discussion 
311 The primary goal of this pilot study was to evaluate the potential efficacy of CBT-I in Veterans 
312 complaining of insomnia during early recovery from AD. We found that CBT-I improved 
313 insomnia more than a control treatment, effects that persisted after treatment ended. 
314 Treatment with CBT-I also improved the self-reported SL, decreased dysfunctional sleep-related 
315 cognitions, and improved sleep hygiene behaviors more than control.  However, CBT-I was not 
316 superior to MO in improving PDA or daytime outcomes.  
317 CBT-I exerted a large effect size on insomnia scores, consistent with those reported in prior 
318 studies (Currie et al., 2004, Arnedt et al., 2011). Thus, CBT-I may be beneficial in treating 
319 insomnia in alcohol dependent Veterans. The durability of improvement in insomnia after the 
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320 end of CBT-I treatment has also been demonstrated in subjects with AD as well as in primary 
321 insomnia (Sivertsen et al., 2006, Currie et al., 2004).
322 Insomnia in AD has been linked with cognitive distortions and dysfunctional beliefs about sleep 
323 (Brooks et al., 2016, Brower et al., 2001). Arnedt and colleagues reported an improvement in 
324 sleep-related cognitive distortions in a series of subjects treated with CBT-I (Arnedt et al., 
325 2007). Our study extends this finding in the context of an RCT of CBT-I. Inadequate sleep 
326 hygiene-related behaviors such as daytime naps, which are commonly seen in this population, 
327 can perpetuate insomnia (Currie et al., 2003). We also extend the literature by demonstrating 
328 that CBT-I treatment differentially improved subjects’ sleep hygiene scores.
329 Commonly reported insomnia symptoms include SL (difficulty falling asleep), NAW (multiple 
330 awakenings after falling asleep) and WASO (time spent awake after initially falling asleep). We 
331 showed a significant decrease in SL with CBT-I treatment, a finding that is consistent with two 
332 prior studies (Currie et al., 2004, Arnedt et al., 2011). However, in our study, CBT-I treatment 
333 was associated with a non-significant improvement in WASO, while in prior studies CBT-I 
334 resulted in significantly greater improvements in WASO. Prior studies have demonstrated that 
335 sustained abstinence from alcohol over time leads to improvements in objective sleep 
336 measures of sleep onset latency, slow wave sleep stages, and REM-sleep-related variables. 
337 However, fragmentation of sleep through the night may persist for up to two years into 
338 sobriety and may increase the risk of relapse (Drummond et al., 1998, Adamson and Burdick, 
339 1973, Williams and Rundell, 1981). In our study, subjects were abstinent on only 27% of the 
340 days during the pretreatment period, whereas in the previous studies they were sober for an 
341 average of 2-4 months (Currie et al., 2004, Arnedt et al., 2011).  Thus, it is possible that the 
342 persistent effects of alcohol on sleep maintenance were more evident in our subjects because 
343 they were still drinking at study entry. The small sample in our study may also have contributed 
344 to the non-significant effect on WASO.
345 The two prior RCTs reported no effect of CBT-I treatment on the number of subjects who 
346 relapsed to alcohol use or the number of days abstinent. Currie and colleagues found that 
347 during the 7-week treatment phase of their study, subjects in individual therapy consumed an 
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348 average of 31.8 drinks on 10.3 drinking days, compared to 60 drinks on 9.7 drinking days in the 
349 wait-list control group. These numbers suggest that either more subjects in the control 
350 condition drank heavily or those who consumed alcohol drank heavily. This contrasts with the 
351 findings of Arnedt et al., where four subjects relapsed to heavy drinking in the CBT-I (N=9) and 
352 behavioral placebo (N=8) groups. However, Arnedt and colleagues used a very stringent 
353 criterion for relapse by considering all dropouts as having relapsed to drinking (Arnedt et al., 
354 2011). In our study, 1 subject in the CBT-I and 2 in the MO groups relapsed to heavy drinking 
355 during the treatment phase. By the end of the post-treatment follow-up phase, three subjects 
356 in each arm had relapsed to heavy drinking. These preliminary data suggest that CBT-I 
357 treatment may not protect against relapse to drinking in recovering subjects. Lastly, the lack of 
358 differential improvement in the daytime functioning measures with CBT-I is similar to that 
359 reported in the prior two clinical trials. 
360 A majority of Veterans who receive care at the Philadelphia CMCVAMC primary site identify 
361 themselves as African American. In addition to being located in Philadelphia, where the 
362 population is evenly divided between European Americans and African Americans, some prior 
363 studies have shown that African-American Veterans are more likely to be treated for substance 
364 use disorders than European-American Veterans (Glass et al., 2010, Williams et al., 2012). 
365 Therefore, it is not surprising that 73% of Veterans in this study identified themselves as African 
366 American. Because of the racial imbalance between the treatment arms, we treated race as a 
367 covariate in our statistical models. Race was an independent predictor of the change in percent 
368 days abstinent over time (β = -9.0, 95% C.I.: -9.7, -8.2), with African-American subjects reporting 
369 a decrease of 9% in the model-estimated mean PDA over time. It is possible that participation in 
370 the study bolstered the social support for these middle-aged, African-American subjects with 
371 co-occurring insomnia, leading to improved self-efficacy and consequently a relatively greater 
372 proportion of abstinent days, as shown previously (Warren et al., 2007, Walton et al., 2001). 
373 However, race was not a significant predictor of improvement in the sleep-related measures (ISI 
374 total score, sleep diary variables, DBAS or SHI), which could have been secondary to the small 
375 sample size that provided inadequate statistical power to detect a difference based on race or 
376 to evaluate psychosocial factors as mediators of racial differences. 
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377 Although we replicated some findings from prior trials and report some novel findings, the 
378 selection of treatment-seeking, alcohol-dependent subjects introduced a selection bias so that 
379 these results may not generalize to all Veterans with AD. The effect sizes could have been 
380 skewed because of the decrease in sample size during the follow-up visits because of the 
381 dropouts. Furthermore, the sample size did not yield sufficient power to detect a difference in 
382 drinking outcomes between the treatment groups over time. Future studies should attempt to 
383 replicate these findings with a larger sample over a longer duration to provide adequate power 
384 to detect differences in drinking outcomes.  Future studies should also use polysomnography to 
385 quantify objective sleep and spectral polysomnographic changes with treatment and evaluate 
386 the role of alcohol as a hypnotic agent. 
387
388 Conclusions. 
389 CBT-I was efficacious for treating insomnia in alcohol-dependent Veterans during early 
390 recovery. However, in this small RCT, it was not superior to the control group in improving 
391 abstinence from alcohol. Adequately-powered studies are required to evaluate the effect of 
392 CBT-I on drinking outcomes and to identify potential moderators of treatment response. 
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551 Figure Legends
552 Figure 2. Legend: ISI = Insomnia Severity Index; wk = week number of visit in the treatment 
553 phase; 6 mo. = 6-month post-treatment follow-up visit; model statistics of mixed effects 
554 maximum likelihood regression using unstructured covariance matrix and adjusted for Race; 
555 time: β = -1.05, p=0.01; treatment: β = 1.5, p = 0.5; treatment x time: β = -1.3, p = 0.03;
556
557 Figure 3. Legend: SL = Sleep Latency (from their sleep diaries); wk = week number of visit in the 
558 treatment phase; 6 mo. = 6-month post-intervention follow-up visit; model statistics of mixed 
559 effects maximum likelihood regression using unstructured covariance matrix and adjusted for 
560 Race; time: β = 2.5, p=0.29; treatment: β = 47.7, p = 0.002; treatment x time: β = 1.5, p <0.0001.
561
562 Figure 4. Legend: DBAS = Dysfunctional Attitudes and Beliefs about Sleep scale; wk = week 
563 number of visit in the treatment phase; 6 mo. = 6-month post-intervention follow-up visit; 
564 model statistics of mixed effects maximum likelihood regression using independent covariance 
565 matrix and adjusted for Race; time: β = 0.03, p=0.49; treatment: β = 0.1, p = 0.84; treatment x 
566 time: β = -0.2, p <0.0001           
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Table 1. Baseline demographic and clinical variables for the total sample and by treatment groups
Treatment groups 
mean (SD)
Variable Total Sample 
mean (SD)  
(N = 22) MO (N = 11) CBT-I (N = 11)
Demographic
Age (yr) 54.5 (6.9) 56 (6) 52 (7)
Gender (male), N (%) 22 (100%) 11 (100%) 11 (100%)
Race (African American), N (%) 16 (73%) 11 (100%) 5 (45%)*
Education (yr) 12 (0.8) 12 (0.9) 12 (0.8)
Unemployed (past month), N (%) 14 (64%) 6 (55%) 8 (73%)
Marital Status (single), N (%) 18 (82%) 9 (82%) 9 (82%)
Sleep
Insomnia Severity Index total score 18.9 (5.4) 19.8 (5.6) 18.0 (5.3)
Sleep Latency (sleep diary, min) 51.4 (50.6) 33.9 (20.3) 69.0 (65.5)
Wake time after sleep onset (sleep diary, min) 38.6 (27.2) 33.7 (26.4) 43.6 (28.4)
Total Sleep Time (sleep diary, min) 286.4 (98.8) 283.1 (115.3) 289.6 (84.7)
Number of Awakenings (sleep diary, min) 1.8 (1.1) 1.6 (1.0) 1.9 (1.2)
Dysfunctional Beliefs & Attitudes mean score 5.4 (1.6) 5.6 (1.7) 5.1 (1.6)
Sleep Hygiene Scale total score 34.7 (5.2) 36.6 (4.0) 32.9 (5.8)
Epworth Sleepiness Scale total score 11.1 (5.2) 13.1 (5.6) 9.1 (4.1)
Alcohol Consumption (TLFB)
Percent Days Abstinent 26.4 (26.3) 25.4 (30.9) 27.4 (22.3)
Proportion of Heavy Drinking Days 0.8 (0.1) 0.8 (0.1) 0.9 (0.2)
Penn Alcohol Craving Scale total score 7.6 (6.8) 9.0 (6.3) 6.1 (7.2)
Daytime Dysfunction
Quick Inventory of Depressive Symptoms1 22.1 (8.3) 22.0 (8.6) 22.3 (8.5)
Trait Subscale (State Trait Anxiety Inventory) 47.3 (7.6) 48.0 (8.7) 46.7 (6.6)
Physical Composite Score (SF-12 scale) 39.6 (4.6) 39.3 (4.0) 40.0 (5.3)
Mental Composite Score (SF-12 scale) 40.1 (5.6) 40.6 (5.0) 39.5 (6.2)
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yr = years; *p = 0.01; 1without the three sleep items 
Hypnotic Medication Prescriptions (N=20)
Any medication for insomnia 8 (40%) 3 (30%) 5 (50%)
Trazodone 4 (20%) 3 (30%) 1 (10%)
Mirtazapine 2 (10%) 0 (0%) 2 (20%)
Gabapentin 1 (5%) 0 (0%) 1 (10%)
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Table 2. Model-estimated mean change in clinical outcomes over time across treatment groups (change from baseline values) 
Variable Change at end of treatment1 Change at 3-month post-treatment follow-up1 Change at 6-month post-treatment follow-up 1
MO 95% C.I. CBT-I 95% C.I. MO 95% C.I. CBT-I 95% C.I. MO 95% C.I. CBT-I 95% C.I.
Sleep
ISI total score -8.4 -16.3, -0.5 -12.7 -15.5, -10.0 -9.4 -18.3, -0.5 -13.4 -16.0, -10.9 -10.5 -20.4, -0.6 -13.9 -16.3, -11.6
SL (min) 20.6 -18.2, 59.5 -45.1 -78.0, -12.2 23.2 -20.5, 67.0 -36.8 -75.9, 2.3 25.8 -22.7, 74.4 -25.4 -71.9, 20.9
WASO (min) -1.7 -17.8, 14.3 -24.5 -40.8, -8.3 -1.9 -20.1, 16.1 -27.6 -45.9, -9.3 -2.1 -22.3, 17.9 -30.7 -51.0, -10.4
TST (min) 45.2 0.8, 89.6 102.4 57.5, 147.3 50.9 0.9, 100.8 115.2 64.7, 165.7 56.5 1.0, 112.0 128.0 71.9, 184.1
NAW -0.06 -1.0, 0.8 -0.27 -1.2, 0.6 -0.07 -1.1, 0.9 -0.30 -1.3, 0.7 -0.08 -1.2, 1.0 -0.3 -1.5, 0.8
DBAS 0.2 -0.5, 1.1 -1.8 -2.6, -0.9 0.3 -0.6, 1.2 -2.0 -2.9, -1.1 0.3 -0.6, 1.3 -2.2 -3.2. -1.2
SHI -0.8 -3.4, 1.7 -4.6 -7.1, -2.0 -0.9 -3.8, 1.9 -5.1 -8.0, -2.3 -1.0 -4.2, 2.2 -5.7 -8.9, -2.5
ESS -0.6 -2.4, 1.0 -3.1 -4.9, -1.4 -0.7 -2.7, 1.1 -3.5 -5.5, -1.5 -0.8 -3.0, 1.3 -3.9 -6.1, -1.7
Alcohol
PDA 0.7 0.6, 0.8 0.7 0.6, 0.8 0.7 0.6, 0.8 0.7 0.6, 0.8 0.7 0.6, 0.8 0.7 0.6, 0.8
PACS -0.5 -3.6, 2.6 - 0.7 - 3.9, 2.3 - 0.6 -4.1, 2.9 -0.8 -4.4, 2.6 - 0.6 -4.6, 3.2 - 0.9 - 4.9, 2.9
Daytime
QIDS -6.0 -10.8, -1.2 - 9.2 -14.0, -4.5 -6.8 -12.1, -1.4 - 10.4 -15.7, -5.1 -7.5 -13.5, -1.5 -11.6 -17.5, -5.6
STAI-Trait 0.4 -3.6, 4.4 -3.9 -7.9, 0.03 0.4 -4.0, 4.9 - 4.4 - 8.9, 0.03 0.5 -4.5, 5.5 - 4.9 - 9.9, 0.04
PCS -0.9 -3.5, 1.7 - 1.4 -4.0, 1.2 -1.0 - 4.0, 1.9 - 1.6 - 4.6, 1.3 - 1.1 - 4.4, 2.2 - 1.8 - 5.1, 1.5
MCS 0.1 - 2.8, 3.1 0.4 - 2.4, 3.4 0.1 - 3.1, 3.5 0.5 - 2.7, 3.8 0.1 - 3.5, 3.9 0.6 - 3.0, 4.3
1As compared to the baseline phase; MO = Standard Care Monitor-Only condition; CBT-I = Cognitive Behavioral Therapy for 
Insomnia; ISI = Insomnia Severity Index total score; SL = Sleep Latency; min = minutes; WASO = Wake After Sleep Onset time; 
TST = Total Sleep Time; NAW = Number of Awakenings; DBAS = Dysfunctional Beliefs and Attitudes about Sleep Scale mean 
score; SHI = Sleep Hygiene Index total score; ESS = Epworth Sleepiness Scale total score; PDA = Percent Days Abstinent; PACS = 
Penn Alcohol Craving Scale total score; QIDS = 16-item Quick Inventory of Depressive Symptomatology; STAI-Trait = State Trait 
Anxiety Inventory – Trait subscale; PCS = Physical Composite Summary Score (from the Short Form 12-item measure);  MCS = 
Mental Composite Summary Score (from the Short Form 12-item measure). The significant between-group differences over 
time are shown in bold.Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved
Au
th
or
 M
an
us
cr
ip
t
Figure 1. CONSORT Flow Diagram of Subjects in the Study 
Assessed for eligibility (n=109) 
Excluded (n=87)    Not meeting inclusion criteria (n=85)    Declined to participate (n=2) 
Analyzed (n=11) 
Discontinued 8-week intervention (n=0)       
Lost to 3-mo post-treatment follow-up 
(unknown reason/s) (n=1)                                      
Lost to 6-mo post-treatment follow-up 
(unknown reason/s) (n=1) 
 
Allocated to CBT-I intervention (n=11)  Received allocated intervention (n=11) 
 
Discontinued 8-week intervention (n=0)        
Lost to 3-mo post treatment follow-up (n=0)         
Lost to 6-mo post-treatment follow-up 
(incarceration) (n=1) 
 
Allocated to MO intervention (n=11)  Received allocated intervention (n=11) 
Analyzed (n=11) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=22) 
Enrollment 
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         Figure 2. Model-estimated changes in Insomnia Severity Index (ISI) total score over time by treatment arm 
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         Figure 3. Model-estimated changes in subjective Sleep Latency (SL) over time by treatment arm 
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 Figure 4. Model-estimated changes in Dysfunctional Beliefs and Attitudes About Sleep (DBAS) mean score over time   
                  by treatment arm 
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